ReviewTargeted oncology2024
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics.
Review in Targeted oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights.The Journal of pathology · 2026Article
- Hypoxia-inducible factors: Regulatory functions and status as a therapeutic target in gastric cancer (Review).Oncology letters · 2026Review
- Optimal upper gastrointestinal surveillance strategies for gastric, small bowel and pancreatic cancer detection in Lynch syndrome.Familial cancer · 2026Review
- Tree-based model for diffuse-type gastric cancer prognostication: a population study based on the Surveillance, Epidemiology, and End Results database.Translational cancer research · 2026Article
- Unique pattern of endometrial invasion in gastric-type adenocarcinoma of the uterine cervix: a report of two cases.International cancer conference journal · 2026Article
- Animal models and pathogenesis of gastric cancer: from premalignant conditions-to-metastasis.Cancer biology & medicine · 2026Review
- Review
- AI-enabled single-cell dissection of the palmitoylation landscape identifies a multicellular prognostic program in gastric cancer.NPJ precision oncology · 2026Article
- Mechanisms of Metabolic Reprogramming Regulating Immunosuppression in the Gastric Cancer Tumor Microenvironment.Biomolecules · 2026Review
- Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.World journal of gastrointestinal oncology · 2026Article
- Integrated multi-omics and machine learning identify EFNA3 as a key biomarker of tumor invasion.Frontiers in immunology · 2026Article
- Molecular Mechanisms and Biomarkers Driving the Transition From Chronic Atrophic Gastritis to Gastric Cancer.Clinical Medicine Insights. Oncology · 2026Review
- Editorial: Innovative pathological approaches for poorly cohesive gastric cancer.Frontiers in oncology · 2026Article
- Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice.Frontiers in oncology · 2026Review
- Uncovering the molecular landscape of young-onset diffuse gastric cancer: A relieff-based feature selection analysis on RNA-Seq data.PloS one · 2026Article
- Molecular Subtypes of Mixed Gastric Cancer Defined by Machine Learning for Predicting Prognosis and Treatment Response.Current medicinal chemistry · 2026Article
- From Antibody Drugs to RNA Interference and Nanotherapy: The Evolution and Integration of Targeted Strategies in Gastric Cancer.International journal of nanomedicine · 2026Review
- Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report.World journal of gastrointestinal oncology · 2025Article
- Mechanical Signaling: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.MedComm · 2025Review
- Evaluation of ARHGAP26 expression, prognostic significance, and immune infiltration in clear cell renal cell carcinoma.Journal, genetic engineering & biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diffuse-type gastric cancer (DGC) accounts for approximately one-third of gastric cancer diagnoses but is a more clinically aggressive disease with peritoneal metastases and inferior survival compared with intestinal-type gastric cancer (IGC). The understanding of the pathogenesis of DGC has been relatively limited until recently. Multiomic studies, particularly by The Cancer Genome Atlas, have better characterized gastric adenocarcinoma into molecular subtypes. DGC has unique molecular features, including alterations in CDH1, RHOA, and CLDN18-ARHGAP26 fusions. Preclinical models of DGC characterized by these molecular alterations have generated insight into mechanisms of pathogenesis and signaling pathway abnormalities. The currently approved therapies for treatment of gastric cancer generally provide less clinical benefit in patients with DGC. Based on recent phase II/III clinical trials, there is excitement surrounding Claudin 18.2-based and FGFR2b-directed therapies, which capitalize on unique biomarkers that are enriched in the DGC populations. There are numerous therapies targeting Claudin 18.2 and FGFR2b in various stages of preclinical and clinical development. Additionally, there have been preclinical advancements in exploiting unique therapeutic vulnerabilities in several models of DGC through targeting of the focal adhesion kinase (FAK) and Hippo pathways. These preclinical and clinical advancements represent a promising future for the treatment of DGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.